Kevin is Chief Operating Officer of Therna Biosciences, where he leads the Company’s operations and business development as Therna converts its platform capability into partnerships and programs.
He brings more than 20 years of experience building and leading biotechnology companies across AI-enabled drug discovery, RNA therapeutics, and pharmaceutical development, spanning corporate strategy, operations, organizational development, portfolio planning, business development, financing, and strategic transactions.
Kevin most recently served as Chief Business Officer of Inceptive, where he shaped corporate and partnering strategy for its AI-driven biological design platform and led a licensing and collaboration transaction with Alnylam Pharmaceuticals. Previously he held multiple executive roles at Elsie Biotechnologies, including Interim Chief Executive Officer and Chief Operating Officer, helping build and position the RNA therapeutics company through its partnership with and subsequent acquisition by GSK. He served as Chief Financial Officer and Senior Vice President of Corporate Development at Bioniz Therapeutics, where he helped lead strategy, operations, financing, and the company’s acquisition by Equillium. Earlier in his career he spent 11 years at Allergan in the finance and corporate development groups.
Kevin received his MBA from the University of California, Irvine and his B.A. from California State University.